Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Pfizer

Wyeth products boost revenues, but a decline is predicted

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer 4Q10

4Q10 Revenues: $17.6 billion (+6%)

4Q10 Earnings: $2.9 billion (+277%)

FY Revenues: $67.8 billion (+36%)

FY Earnings: $8.3 billion (-4%)

Comments: U.S. revenues dropped 3% in 4Q10 to $7.2 billion, while international sales were up 13% to $10.3 billion. For the year, revenues were up $17.8 billion, but the company received a boost of $18.1 billion from legacy Wyeth products and $1.1 billion from exchange rates. Legacy Pfizer products were down 3% for FY. The company announced a $5 billion share buyback program, and plans to cut 2012 R&D to approximately $6.5 to $7.0 billion; 2010 R&D expenditure was $9.4 billion, and included some integration costs. For 2011, the company predicts flat sales, followed by a single-digit decline in 2012. In a statement, new president and chief executive officer Ian Read said the company will look to “an increased level of outsourcing for services that do not drive competitive advantage for Pfizer.” Lipitor sales dropped 17% in 4Q10 to $2.6 billion, led by a 26% fall in international sales.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters